Study of Intracoronary Tirofiban to Treat No-Reflow in Adults With STEMI After Opening the Blocked Artery

What this Trial Is About

This research aims to evaluate the no-reflow phenomenon in patients who have experienced ST-segment-elevation myocardial infarction STEMI, a condition caused by blockage of a coronary artery due to plaque rupture or erosion. The study focuses on the use of intracoronary glycoprotein IIbIIIa inhibitors, specifically tirofiban, after reopening the artery to improve blood flow in these patients. No-reflow is a common cause of complications after STEMI, and the study investigates strategies to address it. Participants will be randomly assigned to receive either intracoronary tirofiban 25 mgkg or a control treatment of intracoronary saline 0.9% solution. Both treatments are delivered directly into the coronary artery after the blocked artery is opened during the primary percutaneous coronary intervention PCI. The study uses a double-blind design to compare the effects of tirofiban versus saline on blood flow and heart event outcomes. Throughout the study, researchers will monitor blood flow within 15 minutes after treatment to assess the primary outcome. They will also track the incidence of major adverse cardiac events for up to 30 days following treatment. Participants will undergo regular evaluations to measure heart function and safety. The entire participation period includes treatment and follow-up to determine treatment impact on blood flow and cardiac events.

No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track